Prevalence of Helicobacter pylori infection in adult patients with dyspeptic symptoms in Abdi Waluyo Hospital Jakarta from January 2017 to December 2019

Irawati, Maureen; Budimutiar, Felix Aloysius; Darmawan, Gumgum; Budimutiar, Deborah Theresia; Simadibrata, Marcellus

doi:10.24871/221202137-41

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Helicobacter pylori is a Gram-negative, microaerophilic spiral-shaped bacterium that infects the epithelial layer of the stomach of affected humans, causing inflammation and ulceration (1). This bacterium remains one of the most common chronic bacterial infections affecting humans, with prevalence rates varying widely among different geographical regions and ethnic groups (2,3). Chronic gastritis following H. pylori infection is associated with an increased risk of upper gastrointestinal diseases, such as peptic ulcer disease (PUD), mucosa-associated lymphoid tissue lymphoma (MALT), and gastric malignancies (4,5).…”

Section: Introductionmentioning

confidence: 99%

Helicobacter pylori Standard Triple Therapy Outcomes in Iranian Population: A Retrospective Population-based Study in Mashhad, Northeast of Iran

AkbariRad

Goshayeshi

Ghalibaf

et al. 2022

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Helicobacter pylori infection is one of the most prevalent infections in many areas of the world, which is treated with different combinations of medications. Objectives: This study aimed to investigate the response rate and outcomes of H. pylori-infected Iranian patients treated with triple therapy. Methods: The current study examined the records of patients with dyspepsia referred to Imam Reza hospital's gastroenterology clinic in Mashhad, Iran, diagnosed with H. pylori from 2017 to 2019. The patients received the triple therapy for H. pylori and were divided into responsive and non-responsive groups. Results: Out of the 750 patients, 477 were included in the study. The response rate to H. pylori standard triple therapy was 79% after 14 days of treatment. Patients aged 30 - 39 years had the highest rate of treatment response. There was no significant relationship between the response rate to treatment and smoking (P = 0.74), alcohol consumption (P = 0.91), opium addiction (P = 0.89), history of aspirin (P = 0.46) or nonsteroidal anti-inflammatory drugs (NSAIDs) use (P = 0.66), diabetes (P = 0.18), renal failure (P = 0.054), and family history of GI malignancies (P = 0.51). Furthermore, patients with gastric ulcer (P = 0.43), duodenal ulcer (P = 0.66), and gastric precancerous lesions (P = 0.93) showed no significant difference in response to treatment. Conclusions: The H. pylori triple therapy regimen can be an effective medication strategy for H. pylori infection in the Iranian population.

show abstract